At just over one year into the COVID-19 pandemic, evolution of SARS-CoV-2 has generated viral variants that differ in their genetic sequence from the strain first detected in December 2019. Evidence is emerging about how these variants differ in their transmission characteristics, associated clinical symptoms, and vaccine efficacy. This document is a brief summary of published evidence about characteristics of SARS-CoV-2 variants that may impact the public health response, including transmission and response to vaccination.
Opinion: If You’re Under 65, Don’t Hesitate to Vaccinate Against COVID-19 (quotes Judith Wasserheit)
I am a 34-year-old open-heart surgery survivor who got the vaccine as part of a science experiment. I don’t regret it.
by Samantha Allen / February 5, 2021
I smiled when the thermometer read 102 degrees.
United World Antiviral Research Network (UWARN) Partners Collaborate to Expand Understanding of New COVID Variants, Key to Future Vaccine Development
The recent recognition of new COVID-19 variants, first detected in South Africa (B.1.135, 501Y.V2), Brazil (P1) and the UK (B.1.1.7) – and the variants’ potential to disrupt vaccine effectiveness and protection from prior COVID-19 infection – is an urgent concern that UWARN partners around the globe are collaborating on to understand.
Rising infections and new, highly contagious strains of the coronavirus are pressuring governments to accelerate vaccinations
By Dasl Yoon in Seoul, Rhiannon Hoyle in Sydney and Felicia Schwartz in Tel Aviv, The Wall Street Journal
Public health experts are racing to prepare communities for the vaccine, but they face notable hurdles.
by Lilly Fowler, Crosscut
Rosalinda Martinez, a 47-year-old immigrant from Mexico who lives in Tukwila, doesn’t plan to receive the COVID-19 vaccine, even though she’s at higher risk of dying from the virus because she’s overweight and diabetic.
Even partial protection of one dose could be enough to slow the spread of the virus, the UW Medicine researchers argue in a paper.
MEDIA CONTACT: Susan Gregg - 206.616.6730, firstname.lastname@example.org
Giving one dose of the COVID-19 vaccines currently approved in the United States could curtail the spread of the SARS-CoV-19 in the community more quickly than the recommended two doses, say two vaccine experts at the University of Washington School of Medicine.
Volunteer enrollment begins for Phase III clinical trial that will determine the efficacy of Novavax vaccine candidate.
UW Medicine investigators are starting volunteer enrollment for an investigational COVID-19 vaccine clinical trial. The Phase III study will examine whether the Novavax vaccine candidate can protect against SARS-CoV-2, the coronavirus responsible for COVID-19.